Community Substance Use Advisory | Regional HIV/AIDS Connection

You are here

Home » Community Substance Use Advisory

Community Substance Use Advisory

August 7, 2024

 

Warning: Dexmedetomidine (veterinary and human sedative) in local fentanyl supply 

Through anecdotal drug testing reports and observations at Carepoint Consumption & Treatment Services, we would like to share the following information about possible side effects that could be associated with batches of fentanyl potentially cut with medetomidine/dexmedetomidine. Please note: The colour of the substance currently associated with this advisory varied.

We urge caution around following possible side effects:  

  •  Deep sedation and/or drowsiness.
  •  Extreme disorientation and ‘loss of time’, memory loss, and/or blackouts.

In the community, a person can present as not responding to stimulation after multiple doses of naloxone, but is breathing and has a pulse. They may appear to be in a deep sleep-like state. It is still important to call 911, giving naloxone is still a vital step in responding. Unregulated substances such as fentanyl are often cut with other drugs. Even a very small amount can cause an overdose or other side effects.

Harm reduction recommendations when using substances:

  • Try not to use alone.
  • Stagger use, if using in a group.
  • If you use alone, tell someone where you are. Ask them to check on you.
  • Use in small doses.
  • Avoid mixing substances, if possible.
  • Encourage use of Carepoint (Mon-Sun: 9AM-9PM).
  • Have naloxone ready and know how to respond to an overdose

For more information, please contact Director of Harm Reduction Services, Megan Van Boheemen, at mvanboheemen@hivaidsconnection.ca or 226.377.8721.  

Posted August 7, 2024. Please remove this notice by August 17, 2024 as the illicit drug supply changes constantly.